Examples of 'methylnaltrexone' in a sentence
Meaning of "methylnaltrexone"
Methylnaltrexone is a drug that is used to treat constipation caused by opioid medications. It works by blocking the effects of opioids in the gut without affecting their ability to relieve pain
Show more definitions
- A peripherally-acting μ-opioid antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals.
How to use "methylnaltrexone" in a sentence
Basic
Advanced
methylnaltrexone
Methylnaltrexone bromide undergoes moderate tissue distribution.
The invention provides stable formulations of methylnaltrexone.
Neither methylnaltrexone or naloxone alone affected migration.
Preparation of an improved room temperature methylnaltrexone forumulation.
Methylnaltrexone is hydrophilic and quite soluble in aqueous solutions.
Relistor contains the active substance methylnaltrexone bromide.
Low doses of methylnaltrexone were administered intravenously.
Provided formulations are useful for parenteral administration of methylnaltrexone.
Methylnaltrexone is a quaternary derivative of the opioid antagonist naltrexone.
The active substance is methylnaltrexone bromide.
Methylnaltrexone also may be adsorbed into the particles.
The invention therefore provides a lyophilized preparation of methylnaltrexone.
Methylnaltrexone also may be dispersed throughout the particles.
Spheroids containing methylnaltrexone were prepared.
Methylnaltrexone bromide is eliminated primarily as the unchanged active substance.
See also
Aqueous solutions of methylnaltrexone are prepared.
Methylnaltrexone bromide is excreted via the milk of lactating rats.
Examples of opioid antagonists include methylnaltrexone and the like.
Formulations of methylnaltrexone may be prepared as a unit dosage form.
The opioid antagonist is a peripheral opioid antagonist which is methylnaltrexone.
The effects of methylnaltrexone bromide in pregnant women are not known.
Inhibition of metal and calcium mediated degradation of methylnaltrexone formulations.
It is unknown whether methylnaltrexone bromide is excreted in human breast milk.
Pharmaceutical formulations containing methylnaltrexone.
Formulations containing methylnaltrexone were prepared using pharmaceutically acceptable excipients.
Stable pharmaceutical formulations of methylnaltrexone.
Add methylnaltrexone to the tank and stir till dissolved.
Various ion pairs were formed using methylnaltrexone and anions.
Methylnaltrexone may also be administered enterally or parenterally by other means.
Animal studies have shown excretion of methylnaltrexone bromide in breast milk.
Methylnaltrexone apparently was assumed to have a structure that was inherently stable.
Relistor is a medicine that contains the active substance methylnaltrexone bromide.
Methylnaltrexone should not be used during pregnancy unless clearly necessary.
Blood samples were obtained for the determination of the pharmacokinetics of methylnaltrexone.
Relistor methylnaltrexone bromide.
We have identified and characterized degradants which accumulate in certain methylnaltrexone solutions.
Use of calcium facilitates methylnaltrexone bromide stability in solution at room temperature.
Such frozen containers may be thawed prior to intravenous administration of methylnaltrexone to a subject.
Methylnaltrexone bromide and pharmaceutically acceptable excipients were combined in an aqueous solution.
Another objective was to evaluate whether methylnaltrexone reduced tapentadol induced constipation in humans.
Methylnaltrexone has not been found to interfere with the analgesic activity of morphine or narcotics.
There are no adequate data with the use of methylnaltrexone bromide in pregnant women.
The effect of methylnaltrexone in reversing the emetic effects of morphine is illustrated herein.
The effect of severe hepatic impairment on the pharmacokinetics of methylnaltrexone has not been studied.
The renal clearance of methylnaltrexone decreased with increasing severity of renal impairment.
Relistor is a solution for injection that contains the active substance methylnaltrexone bromide.
The administration of methylnaltrexone alone was found to produce no noticeable effects in the animals.
Methods of detection of degradants below a designated level are preferred for production of a methylnaltrexone formulation.
The activity of methylnaltrexone bromide has been studied in patients with constipation induced by opioids.
This should be taken into account when prescribing methylnaltrexone bromide for such patients.
